A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia
A Repeated Dose Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Ichikawa, Japan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Participants who have been diagnosed with schizophrenia in accordance with the diagnostic criteria of Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV)
- Participants may be inpatients or outpatients
- Participants who have been taking an oral antipsychotic medication for at least 28 days before the date of informed consent
- Participants with a Positive and Negative Syndrome Scale (PANSS) score of less than or equal to 4 (moderate) at screening
- Participants who have taken risperidone by the start of investigational treatment and the record can be confirmed Exclusion Criteria
- Participants who have been diagnosed with a mental disease other than schizophrenia in accordance with the diagnostic criteria of Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV)
- Participants who have been diagnosed with substance-related disorders (except nicotine and caffeine dependence)
- Participants with complicated parkinson's disease (a progressive disorder of the central nervous system, seen usually in older persons, in which there is muscle weakness, trembling and sweating)
- Participants with a complication of or with a history of convulsive disease such as epilepsy (seizure disorder)
- Participants with a complication of or with a history of cerebro-vascular accident (stroke), neuroleptic malignant syndrome (high fever, rigid muscles, shaking, confusion, sweating more than usual, increased heart rate or blood pressure, or muscle pain or weakness) or physical exhaustion associated with the state of dehydration (lose of water and minerals in the body) or malnutrition
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Paliperidone palmitate 50 mg
Paliperidone palmitate 50 milligram (mg) intramuscular (into the muscle) injection on Days 1, 8, 36 and 64.
|
Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.
Other Names:
|
|
EXPERIMENTAL: Paliperidone palmitate 100 mg
Paliperidone palmitate 100 mg intramuscular injection on Days 1, 8, 36 and 64.
|
Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.
Other Names:
|
|
EXPERIMENTAL: Paliperidone palmitate 150 mg
Paliperidone palmitate 150 mg intramuscular injection on Days 1, 8, 36 and 64.
|
Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.
Other Names:
|
|
EXPERIMENTAL: Paliperidone palmitate 150/ 50 mg
Paliperidone palmitate 150 mg intramuscular injection on Day 1 and paliperidone palmitate 50 mg intramuscular injection on Days 8, 36 and 64.
|
Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 8
Time Frame: Day 8
|
The pre-dose plasma concentration (Cpredose) at Day 8 is defined as the plasma concentration obtained before a dose is given on Day 8.
The mean Cpredose at Day 8 was measured in nanogram per milliliter (ng/ml).
|
Day 8
|
|
Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 36
Time Frame: Day 36
|
The Cpredose at Day 36 is defined as the plasma concentration obtained before a dose is given on Day 36.
The mean Cpredose at Day 36 was measured in ng/ml.
|
Day 36
|
|
Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 64
Time Frame: Day 64
|
The Cpredose at Day 64 is defined as the plasma paliperidone concentration obtained before a dose is given on Day 64.
The mean Cpredose at Day 64 was measured in ng/ml.
|
Day 64
|
|
Paliperidone Pre-dose Plasma Concentration (Cpredose) at Day 92
Time Frame: Day 92
|
The Cpredose at Day 92 is defined as the plasma paliperidone concentration obtained after the treatment interval of the study drug (that is 4 weeks) passed after the final dose (Day 92).
The mean Cpredose at Day 92 was measured in ng/ml.
|
Day 92
|
|
Maximum Observed Plasma Concentration (Cmax) of Paliperidone
Time Frame: Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
|
The Cmax is defined as maximum observed analyte concentration.
|
Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Paliperidone
Time Frame: Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
|
The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.
|
Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
|
|
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)
Time Frame: Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
|
The AUCtau is a measure of the plasma paliperidone concentration from time zero to end of dosing interval.
It is used to characterize drug absorption.
|
Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
|
|
Plasma Paliperidone Concentration at Steady State (Css av)
Time Frame: Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
|
The Css av is defined as value of average analyte concentration at steady-state (after 4 Intramuscular Injections of Paliperidone Palmitate).
|
Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
|
|
Paliperidone Plasma Decay Half-Life (t1/2)
Time Frame: Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
|
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
|
Days 1, 8, 15, 22, 36, 50, 64, 67, 71, 74, 78, 85, 92, 106, 120, 134, 162, 190, 218 and early withdrawal
|
|
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 8
Time Frame: Day 8
|
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment.
Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe).
The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe).
Overall severity was assessed at 5 levels (0 [none, normal]; 1 [Very Mild]; 2 [Mild]; 3 [Moderate]; 4 [severe]).
|
Day 8
|
|
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 22
Time Frame: Day 22
|
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment.
Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe).
The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe).
Overall severity was assessed at 5 levels (0 [none, normal]; 1 [Very Mild]; 2 [Mild]; 3 [Moderate]; 4 [severe]).
|
Day 22
|
|
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 50
Time Frame: Day 50
|
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment.
Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe).
The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe).
Overall severity was assessed at 5 levels (0 [none, normal]; 1 [Very Mild]; 2 [Mild]; 3 [Moderate]; 4 [severe]).
|
Day 50
|
|
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 78
Time Frame: Day 78
|
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment.
Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe).
The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe).
Overall severity was assessed at 5 levels (0 [none, normal]; 1 [Very Mild]; 2 [Mild]; 3 [Moderate]; 4 [severe]).
|
Day 78
|
|
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 92
Time Frame: Day 92
|
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment.
Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe).
The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe).
Overall severity was assessed at 5 levels (0 [none, normal]; 1 [Very Mild]; 2 [Mild]; 3 [Moderate]; 4 [severe]).
|
Day 92
|
|
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 120
Time Frame: Day 120
|
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment.
Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe).
The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe).
Overall severity was assessed at 5 levels (0 [none, normal]; 1 [Very Mild]; 2 [Mild]; 3 [Moderate]; 4 [severe]).
|
Day 120
|
|
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 162
Time Frame: Day 162
|
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment.
Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe).
The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe).
Overall severity was assessed at 5 levels (0 [none, normal]; 1 [Very Mild]; 2 [Mild]; 3 [Moderate]; 4 [severe]).
|
Day 162
|
|
Number of Participants With Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) Score at Day 218
Time Frame: Day 218
|
The DIEPSS is a scale used to evaluate the severity of drug induced extra-pyramidal symptoms occurring during antipsychotic drug treatment.
Scale consists of 8 individual symptom scales with scores ranging from 0 (none/normal) to 4 (severe).
The total score is the average of the 8 item scores, for a total range of 0 (normal) to 4 (severe).
Overall severity was assessed at 5 levels (0 [none, normal]; 1 [Very Mild]; 2 [Mild]; 3 [Moderate]; 4 [severe]).
|
Day 218
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Positive and Negative Syndrome Scale (PANSS) Total Score
Time Frame: Baseline, Day 8, 22, 50, 78 and 92
|
The PANSS is a medical scale that assesses various symptoms of schizophrenia.
The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology).
The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill).
|
Baseline, Day 8, 22, 50, 78 and 92
|
|
Number of Participants With Clinical Global Impression Severity (CGI-S) Score
Time Frame: Baseline, Day 8, 22, 50, 78 and 92
|
The CGI-S rating scale is a 7 point (1-absent, 2-minimal, 3-mild, 4-moderate, 5-moderate severe, 6-severe, 7-extreme) global assessment that measures the clinician's impression of the severity of illness exhibited by a participant.
A rating of 1 is equivalent to "normal, not at all ill" and a rating of 7 is equivalent to "among the most extremely ill participants".
Higher scores indicate worsening.
|
Baseline, Day 8, 22, 50, 78 and 92
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Dopamine Agents
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Paliperidone Palmitate
Other Study ID Numbers
Other Study ID Numbers
- CR013612
- PALM-JPN-2 (OTHER: Janssen Pharmaceutical K.K., Japan)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.